China
-
Chinese biopharma firm parks over 70% of the IPO with cornerstones -
The firm priced its share at HK$158, with the top 15 investors taking around 70% of the offer
-
-
In this table, GlobalCapital Asia offers a glimpse of the bond deals that are in the works
-
Grey areas remain over changes to DCM and ECM bookbuilding
-
-
The $675m deal ticked many boxes for both the issuer and investors and could signal a rebound in appetite
-
In this table, GlobalCapital Asia offers a glimpse of the bond deals that are in the works
-
In this table, GlobalCapital Asia offers a glimpse of the bond deals that are in the works
-
The club deal got interest mainly from Mainland Chinese and Hong Kong banks
-
Chinese homebuilder has lost its investment grade ratings from all three global rating firms
-
The expanded probe brings Chinese developer’s property services unit under the regulator’s fold
